Keryx Bio (KERX) Chairman Buys 40K Shares
More News related to KERX
- Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
- Keryx Biopharmaceuticals to Present at the Merriman Curhan Ford 6th Annual Investor Summit
- Keryx Biopharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
- Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeti
- Beacon Equity Issues Trading Overview for Keryx Biopharmaceuticals
Keryx Biopharmaceuticals (Nasdaq: KERX) Chairman Michael Tarnok disclosed a purchase of 40,000 shares on 5/26 at $0.46, bringing his stake to 191,100.
Shares of KERX are seeing significant upside momentum today (+35%), but it is unclear if the move is related to the recent flurry of insider buying. Volume is much heavier-than-normal.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.
Related Categories
Insider TradesMomentum Movers
Stocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
